Retinoids, the natural and synthetic analogs of vitamin A, are growth-inhibiting and differentiation-inducing agents and show clinical promise as chemopreventive and antineoplastic agents. Fenretinide, a new synthetic retinoid, has antitumor activity in certain in vitro and in vivo model systems and was relatively nontoxic in phase I trials. Based on these data, we designed a phase II study of Fenretinide involving 31 patients with advanced breast cancer [15] and melanoma [16], two cancers shown to be responsive to this agent in preclinical models. Fenretinide was inactive in patients with advanced disease. Toxicity was mild, and reversible. Mucocutaneous side effects occurred in 16 (52%) patients. Nyctalopia developed in three patients one of whom developed decreased B-wave amplitude of the scotopic electroretinogram. The minimal toxicity and significant activity in preclinical studies make this an attractive agent for future breast cancer chemoprevention studies.
Introduction
Retinoids, the natural derivatives and synthetic analogs of vitamin A, are differentiation-inducing and cytostatic anticancer agents. Chemical modification of the basic retinoid structure has produced analogs with enhanced target organ specificity, increased anticarcinogenic activity and reduced toxicity [1] . The retinamides are a new class of synthetic retinoids in which the terminal carboxyl group of retinoic acid is replaced by an N-substituted carboxyamide group [1] . In vitro, the retinamide Fenretinide has antitumor activity against ovary, lung, breast and melanoma tumor cells [1] . Studies in a rat mammary carcinogenesis model, Moon et al.
showed that Fenretinide is effective as chemopreventive, primary, and adjuvant therapy, and augments the anticarcinogenic effects of tamoxifen and ovariectomy [2, 3] . Further, Fenretinide was stored in breast tissue and was significantly less toxic than other retinoids [4] , making Fenretinide ideal for long-term therapy. 
Patients and methods
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Results
Patient characteristics are shown in Reversible grade I-II mucocutaneous toxicities occurred in 52% of patients. Of the patients with breast cancer, 40% developed a rise in their serum cholesterol and 20% in their serum triglycerides, both of which returned to baseline 2-4 weeks after discontinuing therapy or decreasing dosage. Three patients developed reversible nyctalopia, one of whom had a decreased B-wave amplitude of the scotopic ERG.
Discussion
We observed that Fenretinide, like other retinoids, has limited activity as a single agent against advanced breast cancer and melanoma. Although recent data has shown a 41% Fenretinide response rate (22% complete response) when used as primary therapy of rat mammary carcinoma [3] , we observed no partial or complete responses in our breast cancer patients.
The spectrum of Fenretinide toxicity which we and others [4] observed is similar to that of Isotretinoin, although the frequency and degree is less. The rise in serum triglyceride and cholesterol seen only in patients with breast cancer is difficult to explain. Nyctalopia occurred in three patients, one of whom displayed decreased B-wave microvoltage on the scotopic ERG. Another study evaluating Fenretinide's effect on the ERG reported that high-dose therapy (800 mg/day) produced reversible nyctalopia with elevated rod dark adaptation thresholds and depressed scotopic ERG in two of three basal cell carcinoma patients [5] . Costa et al. also found reversible night blindness in 1 of 25 patients treated at a lower dose (300 mg/d) over 6 months [4] . The visual side-effects of Fenretinide and other synthetic retinoids may be due to their interference with vitamin A metabolism. Our recent pharmacokinetic study, revealing a Fenretinide-induced reduction in serum retinol level supports this postulate [6] .
The data from other breast carcinogenesis studies 319 in animals and the low toxicity in this clinical trial support the need for further investigation of Fenretinide in the management of breast cancer. Furthermore, preclinical data showing that Fenretinide enhances tamoxifen efficacy [2] serves as a rationale for clinical studies of this drug combination in breast cancer.
